FDA Approves Gilead's Twice-Yearly Shot for HIV Prevention

The FDA has approved Gilead's (GILD) Yeztugo, a twice-yearly injectable for HIV pre-exposure prophylaxis (PrEP), based on data showing ≥99.9% efficacy in late-stage trials compared to daily oral Truvada; GILD shares have gained 18.6% YTD versus a 4% decline for the industry. As the first long-acting injectable PrEP, Yeztugo addresses adherence and access barriers, potentially expanding PrEP uptake and solidifying Gilead's HIV portfolio amid generic competition for Truvada, though ViiV Healthcare's Apretude is also an existing long-acting option.

Analysis

Gilead Sciences (GILD) has secured a significant regulatory win with the FDA's approval of Yeztugo, its twice-yearly injectable HIV-1 capsid inhibitor for pre-exposure prophylaxis (PrEP), marking a critical development for its dominant HIV franchise. This approval, granted under Priority Review, was underpinned by late-stage studies (PURPOSE 1 and PURPOSE 2) demonstrating ≥99.9% efficacy and superiority over daily oral Truvada in preventing HIV. Yeztugo's unique twice-yearly dosing schedule represents the first such option in the U.S., aiming to improve PrEP adherence and access, thereby potentially expanding the PrEP market, particularly among underserved populations. This development is strategically important for Gilead, which has seen its shares gain 18.6% year-to-date against an industry decline of 4%, as it strengthens its portfolio against generic competition for Truvada and competes with other long-acting injectables like ViiV Healthcare's (GSK-majority owned) Apretude, which is administered every two months. The European Medicines Agency's validation of Yeztugo's Marketing Authorization Application further signals potential for global market expansion, reinforcing Gilead's leadership in HIV treatment and prevention, where its drug Biktarvy already commands over 51% of the U.S. treatment market.

Key Decisions for Investors

• Investors should closely monitor the commercial launch and uptake trajectory of Yeztugo, as its unique twice-yearly dosing and superior efficacy position it to capture significant market share in the HIV PrEP space, potentially driving substantial revenue growth for Gilead.
• Consider the strategic impact of Yeztugo in fortifying Gilead's HIV franchise against generic erosion of Truvada and increasing competition from GSK's Apretude; successful commercialization could further bolster Gilead's market leadership and future earnings.
• While the FDA approval is a major positive catalyst, reflected in GILD's 18.6% year-to-date share price increase, investors should weigh this against the company's current Zacks Rank #3 (Hold) and assess the valuation following this news before making new investment decisions or adjusting existing positions.